Vanderbilt's Kelly Dooley, MD, PhD, MPH, recently received the Research in Action Award from the Treatment Action Group (TAG).

Vanderbilt University Medical Center is set to construct a state-of-the-art BioSafety Level 3 (BSL3) facility for research involving the COVID-19 virus, anthrax and other dangerous microorganisms.

Rebecca Berhanu, MD, assistant professor of Medicine, has joined Vanderbilt's Division of Infectious Diseases as a clinician and researcher.

Vanderbilt researchers describe how certain tuberculosis treatments work and suggest these medications may overcome the threat of drug-resistant tuberculosis.

Since July, investigators in the Vanderbilt Tuberculosis Center have been awarded research grants totaling $5 million.

Tuberculosis (TB) remains an important public health problem, particularly among people infected with the human immunodeficiency virus (HIV).

An international research team led by scientists from Vanderbilt University Medical Center has identified a genetic variant that protects people with HIV from developing active tuberculosis. The variant is near the gene encoding the infection-fighting cytokine IL-12.